The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Phase II study of cemiplimab in patients (pts) with advanced cutaneous squamous cell carcinoma (CSCC): Longer follow-up.
 
Danny Rischin
Research Funding - Bristol-Myers Squibb; Genentech/Roche; GlaxoSmithKline; Merck; Regeneron
Travel, Accommodations, Expenses - Merck
 
Nikhil I. Khushalani
Stock and Other Ownership Interests - Amarin Corporation; Bellicum Pharmaceuticals; Mazor Robotics; Transenterix
Honoraria - Bristol-Myers Squibb; Sanofi
Consulting or Advisory Role - Array BioPharma; AstraZeneca; Bristol-Myers Squibb; EMD Serono; Genentech; HUYA Bioscience International; Immunocore; Incyte; Merck; Regeneron
Research Funding - Amgen (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); GlaxoSmithKline (Inst); HUYA Bioscience International (Inst); Merck (Inst); Novartis (Inst); Regeneron (Inst)
 
Chrysalyne D. Schmults
Leadership - NCCN
Consulting or Advisory Role - Regeneron; Sanofi
Speakers' Bureau - Castle Biosciences; Regeneron
Research Funding - Castle Biosciences; Genentech; Merck; Novartis; Regeneron
 
Alexander David Guminski
Consulting or Advisory Role - Bristol-Myers Squibb; Eisai; Merck; MSD Oncology; Pfizer; Prime Oncology; Regeneron; Sun Pharma
Research Funding - Sun Pharma (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Medivation/Astellas; Merck KGaA; Sun Pharma
 
Anne Lynn S. Chang
Consulting or Advisory Role - Merck; Regeneron
Research Funding - Galderma; Merck; Novartis; Regeneron
 
Karl D. Lewis
Honoraria - Array BioPharma
Consulting or Advisory Role - Array BioPharma; Merck; Regeneron; Roche
Research Funding - alkermes (Inst); Array BioPharma (Inst); Bristol-Myers Squibb (Inst); Incyte (Inst); Iovance Biotherapeutics (Inst); Kartos Therapeutics (Inst); Merck (Inst); Nektar (Inst); Neon Therapeutics (Inst); OncoSec (Inst); Regeneron (Inst); Roche/Genentech (Inst)
Travel, Accommodations, Expenses - alkermes; Merck; Neon Therapeutics; Regeneron; Roche/Genentech
(OPTIONAL) Uncompensated Relationships - Regeneron; Roche/Genentech
 
Annette May Ling Lim
Travel, Accommodations, Expenses - Merck Sharp & Dohme
 
Leonel Fernando Hernandez-Aya
Consulting or Advisory Role - Massive Bio
Speakers' Bureau - Sanofi/Regeneron
Research Funding - Amgen (Inst); Bristol-Myers Squibb (Inst); Corvus Pharmaceuticals (Inst); Immunocore (Inst); MedImmune (Inst); Merck (Inst); Merck Serono (Inst); Polynoma (Inst); Regeneron (Inst); Roche/Genentech (Inst); Takeda (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Sanofi/Regeneron
 
Brett Gordon Maxwell Hughes
Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Eisai; MSD Oncology; Pfizer; Roche; Sanofi/Regeneron
Research Funding - Amgen (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Bristol-Myers Squibb
 
Dirk Schadendorf
Honoraria - 4SC; Array BioPharma; Bristol-Myers Squibb; Immunocore; Incyte; InflarxGmbH; Merck Serono; Merck Sharp & Dohme; Mologen; NeraCare GmbH; Novartis; Pfizer; Philogen; Pierre Fabre; Regeneron; Roche/Genentech; Sandoz; Sanofi/Regeneron; Sun Pharma; Ultimovacs
Consulting or Advisory Role - 4SC; Bristol-Myers Squibb; Incyte; Merck Serono; Merck Sharp & Dohme; Mologen; Novartis; Pierre Fabre; Roche/Genentech; Sanofi/Regeneron
Speakers' Bureau - Bristol-Myers Squibb; Incyte; Merck KGaA; Merck Sharp & Dohme; Novartis; Pierre Fabre; Roche; Sanofi/Regeneron
Research Funding - Bristol-Myers Squibb (Inst); Novartis (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Merck Serono; Merck Sharp & Dohme; Novartis; Pierre Fabre; Roche/Genentech; Sanofi/Regeneron
 
Axel Hauschild
Honoraria - Amgen; Bristol-Myers Squibb; Merck Serono; Merck Sharp & Dohme; Novartis; OncoSec; Philogen; Provectus; Regeneron; Roche; Sanofi/Aventis
Consulting or Advisory Role - Amgen; Bristol-Myers Squibb; Merck Serono; Merck Sharp & Dohme; Novartis; OncoSec; Philogen; Provectus; Regeneron; Roche; Sanofi/Aventis
Research Funding - Amgen; Bristol-Myers Squibb; Merck Serono; Merck Sharp & Dohme; Novartis; Regeneron; Roche
Travel, Accommodations, Expenses - Amgen; Bristol-Myers Squibb; Merck Serono; Merck Sharp & Dohme; Novartis; Roche; Sanofi/Aventis
 
Elizabeth Stankevich
Employment - Regeneron
Stock and Other Ownership Interests - Bristol-Myers Squibb; Merck; Regeneron
 
Jocelyn Booth
Employment - Alnylam (I); Regeneron
Stock and Other Ownership Interests - Alnylam (I); Regeneron; Regeneron (I)
 
Siyu Li
Employment - Regeneron
Stock and Other Ownership Interests - Regeneron
 
Zhen Chen
Employment - Regeneron
Stock and Other Ownership Interests - Regeneron
 
Emmanuel Okoye
Employment - Regeneron
Stock and Other Ownership Interests - Regeneron
 
Israel Lowy
Employment - Regeneron
Stock and Other Ownership Interests - Regeneron
Patents, Royalties, Other Intellectual Property - Regeneron
 
Matthew G. Fury
Employment - Regeneron; Regeneron (I)
Stock and Other Ownership Interests - Regeneron; Regeneron (I)
Research Funding - Regeneron
Patents, Royalties, Other Intellectual Property - Regeneorn; Regeneron (I)
 
Michael Robert Migden
Consulting or Advisory Role - Rakuten Medical; Regeneron; Sun Pharma
Research Funding - PellePharm; Regeneron
Travel, Accommodations, Expenses - Regeneron; Sun Pharma